Orellana et al. were the first to design and synthesize folate–miR-34a and showed that folate–miR-34a was selectively targeted to FOLR1-expressing tumors, downregulated target genes, and suppressed the tumor growth in vivo in lung and breast cancers [21]. The gene discussed is FOLR1; the disease is neoplasm.